Cizzle Biotechnology Holdings (LSE:CIZ) told investors it will present at the SYNLAB 12th Innovation Academy Symposium on 5 November, co-presenting technical evaluation studies of its CIZ1B lung cancer biomarker test being conducted at the Christie Pathology Partnership in Manchester.
The London-listed diagnostics developer is using the NHS partner event to showcase test improvements that were recently published in peer-reviewed form in The Journal of Applied Laboratory Medicine.
The paper, co-authored with researchers from the University of York, evidences accuracy and reproducibility standards for the CIZ1B test that the company says meet those required by major healthcare service providers.
"The progress we have made this year has enabled precise and reproducible measurement of the CIZ1B lung cancer biomarker, using scalable reagents that will be the foundation of a future high-throughput test kit," said Dawn Coverley, Cizzle's chief scientific officer.
Cizzle maintains a research and collaboration agreement with the University of York that supports development of CIZ1B test improvements and independent validation of the assay for early-stage lung cancer.
The company has built its commercial position around CLIA accreditation secured in the US in June, which opened a regulated laboratory route allowing licensed American healthcare providers to order the test through partner laboratories, alongside royalty-bearing licensing arrangements covering North America and the Caribbean.
Read more about Cizzle Biotechnology
- 15/07/26Cizzle Biotechnology gains US accreditation for lung cancer test
- 16/06/26Cizzle Biotechnology Holdings shares skyrocketed after US CLIA approval
- 12/06/26Cizzle Biotechnology Holdings shares up on US patent grant
Cizzle is now working with commercial partners and cancer-care centres of excellence, including the Christie Pathology Partnership and SYNLAB, to support adoption of the CIZ1B test in the UK, where the board has previously said it is targeting NHS pathways as part of its wider push into Europe and Asia-Pacific.